Publications by authors named "S J Shewale"
Background: To ensure the acceptability and effectiveness of potential Multipurpose Prevention Technologies (MPTs), understanding user needs, and preferences are crucial to inform the design of MPTs. This article aims to explore the perceptions towards potential MPT use and to explore the needs of multiple stakeholders in India within their social and behavioural contexts.
Methods: A qualitative multicentric study was conducted in three Indian states-Maharashtra, Karnataka, and Tamil Nadu.
Background: Combination vaccines are effective in simplifying complex vaccination schedules involving multiple vaccines. A fully liquid hexavalent diphtheria (D)-tetanus (T)-whole-cell pertussis (wP)- hepatitis B (HepB)-inactivated poliovirus (IPV)-Haemophilus influenzae b (Hib) vaccine (HEXASIIL®), manufactured by Serum Institute of India Pvt. Ltd.
View Article and Find Full Text PDFA fully liquid hexavalent containing Diphtheria (D), Tetanus (T) toxoids, whole cell Pertussis (wP), Hepatitis B (Hep B), type 1, 2, 3 of inactivated poliovirus (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (DTwP-HepB-IPV-Hib vaccine, HEXASIIL) was tested for lot-to-lot consistency and non-inferiority against licensed DTwP-HepB-Hib + IPV in an open label, randomized Phase II/III study. In Phase III part, healthy infants received DTwP-HepB-IPV-Hib or DTwP-HepB-Hib + IPV vaccines at 6, 10 and 14 weeks of age. Blood samples were collected prior to the first dose and 28 days, post dose 3.
View Article and Find Full Text PDFArticle Synopsis
- A study aimed to assess the effectiveness and safety of a new quadrivalent HPV vaccine (Cervavac) developed in India, targeting HPV types 6, 11, 16, and 18, particularly in the 9-14 years age group.
- Conducted across 12 hospitals in India, the randomized trial involved healthy participants aged 9-14, comparing Cervavac with the Gardasil vaccine, while maintaining blinding for participants and researchers.
- Results focused on measuring the immune response 30 days after vaccination to ensure that Cervavac matched or exceeded the effectiveness of Gardasil in generating antibodies against HPV.
Background: This study assessed the safety and immunogenicity of a new booster vaccine against tetanus, diphtheria, and pertussis manufactured by Serum Institute of India Pvt. Ltd (SIIPL Tdap).
Methods: The Phase II/III trial was randomized (2:1), observer blinded and active controlled.